July 16, 2014
A New Era in Hepatitis C Treatment
Until recently, treating hepatitis C (HCV) required 24 weeks or more of weekly injections with a regimen including peginterferon alfa. These drug combinations often failed to cure the HCV infection and came with many side effects.
However, it's been a breakthrough year for HCV treatment, with many new, more effective and safer options taking the spotlight. Spearheading the way has been sofosbuvir (Sovaldi), a nucleotide polymerase inhibitor that allows for oral dosing, interferon-free treatment for many and a shorter treatment course.
But the drug's introduction -- and its high baseline price tag -- has stirred considerable debate. Let's examine the brief history of sofosbuvir and how its controversial price could impact future health care costs.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
|What Do the START Results Mean for HIV-Positive People?|
|This Week in HIV Research: HIV Reservoirs Remain Obstacles to Cure; "Redesigned" Antibodies Show Promise; and Is 85% Adherence Enough?|
|HIV-Positive Individuals on Treatment Lose More Years of Life to Smoking Than to HIV|
|More Age-Related Illnesses in Older People With HIV Than Comparable HIV-Negatives|
|Advocates for Women Talk About CROI 2015|
|Statin Therapy for 1 Year Linked to Gains in Bone Density With HIV|